Common use of Commencement and period of agreement Clause in Contracts

Commencement and period of agreement. 2.1 This data collection arrangement shall take effect on publication of the managed access agreement. The data collection period is anticipated to conclude in June 2023 based on the pivotal XXXXXX study. The final patient in this study will be followed up until this time point. The process for exiting the Cancer Drugs Fund will begin at this point and the review of the NICE guidance will start.

Commencement and period of agreement. 2.1 This data collection arrangement shall take effect on publication of the managed access agreement. The data collection period is anticipated to conclude in June December 2023 based on the pivotal XXXXXX study. The final patient in this study will be followed up until this time point(see section 5). The process for exiting the Cancer Drugs Fund will begin at this point and the review of the NICE guidance will start.

Commencement and period of agreement. 2.1 This data collection arrangement shall take effect on publication of the managed access agreement. The data collection period is anticipated to conclude in June 2023 based on 2020, when it is expected that mature overall survival data will be available from the pivotal XXXXXX study. The final patient in this study will be followed up until this time pointENGOT-OV16/NOVA trial (see section 5.1). The process for exiting the Cancer Drugs Fund will begin at this point and the review of the NICE guidance will start.

Commencement and period of agreement. 2.1 This data collection arrangement shall take effect on publication of the managed access agreement. The data collection period is anticipated to conclude in June 2023 based on the pivotal XXXXXX study. The final patient in this study will be followed up until this time pointJuly 2022. The process for exiting the Cancer Drugs Fund will begin at this point and the review of the NICE guidance will start.

Commencement and period of agreement. 2.1 This data collection arrangement shall take effect on publication of the managed access agreement. The data collection period is anticipated to conclude in June 2023 based on December 2021, when final overall survival data from the pivotal XXXXXX study. The final patient in this study will ARIEL3 trial are expected to be followed up until this time pointavailable (see Section 5). The process for exiting the Cancer Drugs Fund will begin at this point and the review of the NICE guidance will start.